Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Nov;575(7781):217-223.
doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon  1 , Karen Rex #  2 , Anne Y Saiki #  2 , Christopher Mohr  2 , Keegan Cooke  2 , Dhanashri Bagal  3 , Kevin Gaida  2 , Tyler Holt  2 , Charles G Knutson  4 , Neelima Koppada  4 , Brian A Lanman  2 , Jonathan Werner  2 , Aaron S Rapaport  3 , Tisha San Miguel  2 , Roberto Ortiz  4   5 , Tao Osgood  2 , Ji-Rong Sun  2 , Xiaochun Zhu  4   6 , John D McCarter  2 , Laurie P Volak  4   7 , Brett E Houk  8 , Marwan G Fakih  9 , Bert H O'Neil  10 , Timothy J Price  11   12 , Gerald S Falchook  13 , Jayesh Desai  14 , James Kuo  15 , Ramaswamy Govindan  16 , David S Hong  17 , Wenjun Ouyang  3 , Haby Henary  8 , Tara Arvedson  3 , Victor J Cee  2 , J Russell Lipford  18
Affiliations
Clinical Trial

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon et al. Nature. 2019 Nov.

Abstract

KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours1,2. The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclinical activity3-5. Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity. Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clinical development. In preclinical analyses, treatment with AMG 510 led to the regression of KRASG12C tumours and improved the anti-tumour efficacy of chemotherapy and targeted agents. In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumour microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors. Cured mice rejected the growth of isogenic KRASG12D tumours, which suggests adaptive immunity against shared antigens. Furthermore, in clinical trials, AMG 510 demonstrated anti-tumour activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barbacid, M. ras genes. Annu. Rev. Biochem. 56, 779–827 (1987). - DOI
    1. Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017). - DOI
    1. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013). - DOI
    1. Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316–329 (2016). - DOI
    1. Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578–589 (2018). - DOI

Publication types

MeSH terms